IRVINE, CA--(Marketwired - January 06, 2014) -
ChromaDex® Corporation (OTCBB: CDXC
) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today its CEO Frank Jaksch will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air on Monday, January 6, 2014, at 2:45pm CST / 12:45pm PST / 3:45pm EST.
We encourage all investors, institutional analysts, industry professionals, customers and others who are interested in learning more about ChromaDex's recent developments to tune in and listen live via iHeart Radio stream. Details below.
Live Interview via iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
Date: January 6, 2014
Time: 2:45pm CST | 12:45pm PST | 3:45pm EST
Network: Clear Channel
Station: DFW 1190AM
Host: Michael Yorba
About Clear Channel: Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX www.clearchannel.com
About Michael Yorba: Michael Yorba is the featured host of Clear Channel's DFW 1190AM in Dallas-Ft.Worth. TX. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics, and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on Internet, television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
A www.1800PublicRelations.com PR Event